Table 2 Participant demographics at baseline in a multi-site, parallel arm, fixed dose, randomised controlled trial of 190 participants with cancer and anorexia comparing megestrol or dexamethasone with placebo.
Megestrol acetate 480 mg/day (N = 61) | Dexamethasone 4 mg/day (N = 67) | Placebo (N = 62) | |
|---|---|---|---|
Age at screening, years, mean (SD) | 71.4 (10.9) | 71.2 (12.7) | 74.7 (10.0) |
Gender, n (%) | |||
Male | 36 (59.0%) | 39 (58.2%) | 39 (62.9%) |
Female | 25 (41.0%) | 28 (41.8%) | 23 (37.1%) |
Weight, kg, mean (SD) | 63.1 (14.0) | 62.5 (14.6) | 62.9 (13.9) |
n = 58 | n = 64 | n = 58 | |
Height, cm, mean (SD) | 167.6 (9.9) | 167.1 (10.2) | 168.2 (10.2) |
n = 57 | n = 60 | n = 57 | |
BMI, kg/m2, mean (SD) | 22.36 (3.95) | 21.97 (4.00) | 22.22 (3.55) |
n = 55 | n = 60 | n = 56 | |
ECOG performance status | |||
0 | 0 (0.0%) | 1 (1.5%) | 1 (1.6%) |
1 | 15 (24.6%) | 13 (19.4%) | 18 (29.0%) |
2 | 29 (47.5%) | 29 (43.3%) | 31 (50.0%) |
3 | 16 (26.2%) | 24 (35.8%) | 12 (19.4%) |
4 | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) |
AKPS score, median (min, max) | 70 (30, 90) | 60 (20, 90) | 70 (20, 90) |
Baseline NRS for appetite, median (min, max) | 3 (0, 4) | 2 (0, 4) | 3 (0, 4) |
